

Marco Picardi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1680939/publications.pdf>

Version: 2024-02-01

105
papers

3,572
citations

159585
30
h-index

149698
56
g-index

106
all docs

106
docs citations

106
times ranked

4389
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of a cardio-oncology unit on prevention of cardiovascular events in cancer patients. ESC Heart Failure, 2022, 9, 1666-1676.	3.1	9
2	Prognostic value of Bcl2 and Bcl6 in primary cutaneous large B-cell lymphoma: A systematic review and meta-analysis. Pathology Research and Practice, 2022, 232, 153812.	2.3	2
3	Sulfur Hexafluoride Contrast-Enhanced Ultrasound Showing Early Wash-Out of Marked Degree Identifies Lymphoma Invasion of Spleen with Excellent Diagnostic Accuracy: A Monocentric Study of 260 Splenic Nodules. Cancers, 2022, 14, 1927.	3.7	3
4	Liposomal doxorubicin supercharge-containing front-line treatment in patients with advanced-stage diffuse large B-cell lymphoma or classical Hodgkin lymphoma: Preliminary results of a single-centre phase II study. British Journal of Haematology, 2022, 198, 847-860.	2.5	9
5	Role of chromatin assembly factor-1/p60 and poly [ADP-ribose] polymerase 1 in mycosis fungoides. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 478, 961-968.	2.8	5
6	Regarding "Hepatitis B Surface Antigen Positivity is an Independent Unfavorable Prognostic Factor in Diffuse Large B-Cell Lymphoma in the Rituximab Era". Oncologist, 2021, 26, e1083-e1084.	3.7	1
7	Correspondence in reference to the previously published Epub manuscript: "Murt Ahmet et al. Hepatitis B reactivation in hematopoietic stem cell transplanted patients: 20 years of experience of a single center from a middle endemic country. Annals of Hematology 2020; 99: 2671-2677". Annals of Hematology, 2021, 100, 1631-1633.	1.8	1
8	Prognostic Significance of CD30 in Transformed Mycosis Fungoides. American Journal of Clinical Pathology, 2021, 156, 350-355.	0.7	6
9	Prognostic value of Bcl2 and p53 in Hodgkin lymphoma: A systematic review and meta-analysis. Pathology Research and Practice, 2021, 219, 153370.	2.3	2
10	Correspondence in reference to the previously published Epub manuscript by Peter Hokland et al. "How I treat advanced Hodgkin lymphoma" a global view. Br J Haematol. 2020;190:837-850. British Journal of Haematology, 2021, 193, e5-e8.	5.0	2
11	Rituximab-Containing Risk-Adapted Treatment Strategy in Nodular Lymphocyte Predominant Hodgkin Lymphoma: 7-Years Follow-Up. Cancers, 2021, 13, 1760.	3.7	7
12	Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial. Lancet Haematology, 2021, 8, e410-e421.	4.6	83
13	A Novel Approach to Classification and Reporting of Lymph Node Fine-Needle Cytology: Application of the Proposed Sydney System. Diagnostics, 2021, 11, 1314.	2.6	15
14	Chemotherapy-Induced Remission of Steroid-Dependent Ulcerative Colitis Associated With Rectal Hodgkin Lymphoma. Inflammatory Bowel Diseases, 2021, 27, e81-e82.	1.9	1
15	Hashimoto Thyroiditis in Primary Thyroid Non-Hodgkin Lymphoma. American Journal of Clinical Pathology, 2020, 153, 156-164.	0.7	30
16	An 1H NMR study of the cytarabine degradation in clinical conditions to avoid drug waste, decrease therapy costs and improve patient compliance in acute leukemia. Anti-Cancer Drugs, 2020, 31, 67-72.	1.4	1
17	Automatic Prediction and Assessment of Treatment Response in Patients with Hodgkin's Lymphoma Using a Whole-Body DW-MRI Based Approach. Diagnostics, 2020, 10, 702.	2.6	2
18	Borrelia burgdorferi in primary cutaneous lymphomas: a systematic review and meta-analysis. JDDG - Journal of the German Society of Dermatology, 2020, 18, 1379-1384.	0.8	16

#	ARTICLE	IF	CITATIONS
19	HIV prevalence in primary central nervous system lymphoma: A systematic review and meta-analysis. Pathology Research and Practice, 2020, 216, 153192.	2.3	14
20	Involvement of Helicobacter Pylori in Ocular Adnexa Lymphoma. Pathology and Oncology Research, 2020, 26, 2075-2081.	1.9	6
21	Consolidation Radiotherapy Could Be Safely Omitted in Advanced Hodgkin Lymphoma With Large Nodal Mass in Complete Metabolic Response After ABVD: Final Analysis of the Randomized GITIL/FIL HD0607 Trial. Journal of Clinical Oncology, 2020, 38, 3905-3913.	1.6	36
22	Candidaemia in haematological malignancy patients from a SEIFEM study: Epidemiological patterns according to antifungal prophylaxis. Mycoses, 2020, 63, 900-910.	4.0	10
23	Stage I-II nodular lymphocyte-predominant Hodgkin lymphoma: a multi-institutional study of adult patients by ILROG. Blood, 2020, 135, 2365-2374.	1.4	30
24	Consolidation radiotherapy following positron emission tomography complete response in early-stage Hodgkin lymphoma: a meta-analysis. Leukemia and Lymphoma, 2020, 61, 1610-1617.	1.3	5
25	Hepatitis C virus in MALT-lymphoma of the ocular adnexa. Pathology Research and Practice, 2020, 216, 152864.	2.3	8
26	Sjögren Syndrome in Primary Salivary Gland Lymphoma. American Journal of Clinical Pathology, 2020, 153, 719-724.	0.7	14
27	Combined Oral Fentanyl Citrate and Midazolam as Premedication for Bone Marrow Aspiration and Biopsy in Patients with Hematological Malignancies: A Randomized, Controlled and Patient-Blinded Clinical Trial. Journal of Clinical Medicine, 2020, 9, 395.	2.4	4
28	Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study. Blood, 2020, 135, 735-742.	1.4	86
29	Clinical features associated with high pathological grade in primary thyroid lymphoma. Pathology Research and Practice, 2020, 216, 152819.	2.3	7
30	Pegfilgrastim in primary prophylaxis of febrile neutropenia in elderly patients with hematological malignancies: bendamustine and G-CSF support. Supportive Care in Cancer, 2019, 27, 1587-1588.	2.2	10
31	Adding hydroxyurea in combination with ruxolitinib improves clinical responses in hyperproliferative forms of myelofibrosis. Cancer Medicine, 2019, 8, 2802-2809.	2.8	7
32	Microfluidic chip technology applied to fine needle aspiration cytology samples for IGH clonality assessment. Diagnostic Cytopathology, 2019, 47, 749-757.	1.0	3
33	Fungaemia in haematological malignancies: SEIFEM 2015 survey. European Journal of Clinical Investigation, 2019, 49, e13083.	3.4	20
34	Brentuximab vedotin followed by bendamustine supercharge for refractory or relapsed Hodgkin lymphoma. Blood Advances, 2019, 3, 1546-1552.	5.2	23
35	Tenofovir vs lamivudine for the prevention of hepatitis B virus reactivation in advanced-stage DLBCL. Blood, 2019, 133, 498-501.	1.4	16
36	Brentuximab Vedotin with Chemotherapy for Stage 3/4 Classical Hodgkin Lymphoma (cHL): 4-Year Update of the Echelon-1 Study. Blood, 2019, 134, 4026-4026.	1.4	0

#	ARTICLE	IF	CITATIONS
37	Febrile events in acute lymphoblastic leukemia: a prospective observational multicentric SEIFEM study (SEIFEM-2012/B ALL). <i>Annals of Hematology</i> , 2018, 97, 791-798.	1.8	10
38	Safety and comfort of domestic bortezomib injection in real-life experience. <i>Supportive Care in Cancer</i> , 2018, 26, 3111-3116.	2.2	2
39	Rituximab in a risk-adapted treatment strategy gives excellent therapeutic results in nodular lymphocyte-predominant Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2018, 182, 715-718.	2.5	4
40	Infections in Patients with Lymphoproliferative Diseases Treated with Target Therapy. Italian Multicentric Retrospective Study Seifem 2017. <i>Blood</i> , 2018, 132, 4164-4164.	1.4	4
41	Adding Hydroxyurea in Combination with Ruxolitinib Improves Clinical Responses in Hyperproliferative Forms of Myelofibrosis. <i>Blood</i> , 2018, 132, 4290-4290.	1.4	0
42	Prognostic Relevance of Neutrophil to Lymphocyte Ratio (NLR) and Lymphocyte to Monocyte Ratio (LMR) in Newly Diagnosed Advanced-Stage Hodgkin Lymphoma Patients Treated up-Front with a PET-2 Risk Adapted Protocol. <i>Blood</i> , 2018, 132, 2934-2934.	1.4	0
43	Management of iron overload in myelodysplastic syndromes: combined deferasirox and deferoxamine in a patient with liver disease. <i>Blood Transfusion</i> , 2018, 16, 32-35.	0.4	0
44	Ultrasonography-driven combination antibiotic therapy with tigecycline significantly increases survival among patients with neutropenic enterocolitis following cytarabine-containing chemotherapy for the remission induction of acute myeloid leukemia. <i>Cancer Medicine</i> , 2017, 6, 1500-1511.	2.8	14
45	Changes in the incidence of candidemia and related mortality in patients with hematologic malignancies in the last ten years. A SEIFEM 2015-B report. <i>Haematologica</i> , 2017, 102, e407-e410.	3.5	17
46	Ruxolitinib rechallenge in combination with hydroxyurea is effective in reverting cachexia and reducing blood transfusion demand and splenomegaly symptoms in a patient with primary myelofibrosis. <i>Annals of Hematology</i> , 2017, 96, 697-699.	1.8	10
47	Pegfilgrastim in primary prophylaxis of febrile neutropenia following frontline bendamustine plus rituximab treatment in patients with indolent non-Hodgkin lymphoma: a single center, real-life experience. <i>Supportive Care in Cancer</i> , 2017, 25, 839-845.	2.2	20
48	Viral Outcome in Patients with Occult HBV Infection or HCV-Ab Positivity Treated for Lymphoma. <i>Annals of Hepatology</i> , 2017, 16, 198-206.	1.5	20
49	Hepatitis B and NAFLD: Lives Crossed. <i>Annals of Hepatology</i> , 2017, 16, 185-187.	1.5	14
50	Retreatment with Bendamustine-Bortezomib-Dexamethasone in a Patient with Relapsed/Refractory Multiple Myeloma. <i>Case Reports in Hematology</i> , 2016, 2016, 1-3.	0.4	4
51	Longitudinal strain of left ventricular basal segments and E/e' ratio differentiate primary cardiac amyloidosis at presentation from hypertensive hypertrophy: an automated function imaging study. <i>Echocardiography</i> , 2016, 33, 1335-1343.	0.9	27
52	CD10, BCL6, and MUM1 expression in diffuse large B-cell lymphoma on FNA samples. <i>Cancer Cytopathology</i> , 2016, 124, 135-143.	2.4	30
53	Lymph Node Fine-Needle Cytology of Non-Hodgkin Lymphoma: Diagnosis and Classification by Flow Cytometry. <i>Acta Cytologica</i> , 2016, 60, 302-314.	1.3	42
54	Managing neutropenia by pegfilgrastim in patients affected by relapsed/refractory multiple myeloma treated with bendamustine-bortezomib-dexamethasone. <i>Supportive Care in Cancer</i> , 2016, 24, 4835-4837.	2.2	12

#	ARTICLE	IF	CITATIONS
55	Risk of invasive fungal infection in patients affected by acute promyelocytic leukaemia. A report by the <sc>SEIFEM</sc> registry. British Journal of Haematology, 2015, 170, 434-439.	2.5	14
56	Pre-chemotherapy risk factors for invasive fungal diseases: prospective analysis of 1,192 patients with newly diagnosed acute myeloid leukemia (SEIFEM 2010-a multicenter study). Haematologica, 2015, 100, 284-292.	3.5	64
57	Predicting radiation-induced valvular heart damage. Acta Oncologica, 2015, 54, 1796-1804.	1.8	30
58	Modeling the risk of radiation-induced lung fibrosis: Irradiated heart tissue is as important as irradiated lung. Radiotherapy and Oncology, 2015, 117, 36-43.	0.6	53
59	Pegfilgrastim in primary prophylaxis of febrile neutropenia during chemotherapy of relapsed and refractory multiple myeloma: a real-life experience. Supportive Care in Cancer, 2015, 23, 301-302.	2.2	13
60	Role of lenalidomide in the management of myelodysplastic syndromes with del(5q) associated with pure red cell aplasia (PRCA). Annals of Hematology, 2015, 94, 531-534.	1.8	12
61	Bloodstream Infections in Hematological Cancer Patients Colonized By Multiresistant Bacteria: Results of a Multicentric Prospective Observational Seifem Study. Blood, 2015, 126, 1023-1023.	1.4	0
62	Epidemiology of Fungemia in Hematological Malignancies: Preliminary Report of Seifem-2015 Survey. Blood, 2015, 126, 4887-4887.	1.4	1
63	Pulmonary damage in Hodgkin's lymphoma patients treated with sequential chemo-radiotherapy: Predictors of radiation-induced lung injury. Acta Oncologica, 2014, 53, 613-619.	1.8	34
64	Lymph node fine needle Cytology in the staging and follow-up of Cutaneous Lymphomas. BMC Cancer, 2014, 14, 8.	2.6	30
65	Selective strong synergism of Ruxolitinib and second generation tyrosine kinase inhibitors to overcome bone marrow stroma related drug resistance in chronic myelogenous leukemia. Leukemia Research, 2014, 38, 236-242.	0.8	24
66	Advanced-stage Hodgkin Lymphoma: US/Chest Radiography for Detection of Relapse in Patients in First Complete Remission—A Randomized Trial of Routine Surveillance Imaging Procedures. Radiology, 2014, 272, 262-274.	7.3	37
67	Results of a Multicenter, Controlled, Randomized Clinical Trial Evaluating the Combination of Piperacillin/Tazobactam and Tigecycline in High-Risk Hematologic Patients With Cancer With Febrile Neutropenia. Journal of Clinical Oncology, 2014, 32, 1463-1471.	1.6	55
68	Systemic antifungal treatment after posaconazole prophylaxis: results from the SEIFEM 2010-C survey. Journal of Antimicrobial Chemotherapy, 2014, 69, 3142-3147.	3.0	21
69	Complication Probability Models for Radiation-Induced Heart Valvular Dysfunction: Do Heart-Lung Interactions Play a Role?. PLoS ONE, 2014, 9, e111753.	2.5	39
70	Fine-Needle Cytology and Flow Cytometry Assessment of Reactive and Lymphoproliferative Processes of the Breast. Acta Cytologica, 2012, 56, 130-138.	1.3	17
71	Thyroid V30 Predicts Radiation-Induced Hypothyroidism in Patients Treated With Sequential Chemo-Radiotherapy for Hodgkin's Lymphoma. International Journal of Radiation Oncology Biology Physics, 2012, 82, 1802-1808.	0.8	76
72	Evaluation of the Practice of Antifungal Prophylaxis Use in Patients With Newly Diagnosed Acute Myeloid Leukemia: Results From the SEIFEM 2010-B Registry. Clinical Infectious Diseases, 2012, 55, 1515-1521.	5.8	77

#	ARTICLE	IF	CITATIONS
73	Immunoglobulin heavyâ€chain fluorescence in situ hybridizationâ€chromogenic in situ hybridization DNA probe split signal in the clonality assessment of lymphoproliferative processes on cytological samples. <i>Cancer Cytopathology</i> , 2012, 120, 390-400.	2.4	25
74	Early Treatment Intensification in Advanced-Stage High-Risk Hodgkin Lymphoma (HL) Patients, with a Positive FDG-PET Scan After Two ABVD Courses â€ First Interim Analysis of the GITIL/FIL HD0607 Clinical Trial. <i>Blood</i> , 2012, 120, 550-550.	1.4	8
75	Efficacy and safety of rituximab treatment in patients with progressive transformation of germinal centers after Hodgkin lymphoma in complete remission post-induction chemotherapy and radiotherapy. <i>Leukemia and Lymphoma</i> , 2011, 52, 2082-2089.	1.3	9
76	Dosimetric predictors of asymptomatic heart valvular dysfunction following mediastinal irradiation for Hodgkinâ€™s lymphoma. <i>Radiotherapy and Oncology</i> , 2011, 101, 316-321.	0.6	43
77	Massive-Scale RNA-Seq Analysis of Non Ribosomal Transcriptome in Human Trisomy 21. <i>PLoS ONE</i> , 2011, 6, e18493.	2.5	62
78	SHP-1 expression accounts for resistance to imatinib treatment in Philadelphia chromosomeâ€positive cells derived from patients with chronic myeloid leukemia. <i>Blood</i> , 2011, 118, 3634-3644.	1.4	46
79	Impact of endoscopic ultrasoundâ€guided fine needle aspiration (EUSâ€FNA) in lymph nodal and mediastinal lesions: A multicenter experience. <i>Diagnostic Cytopathology</i> , 2011, 39, 723-729.	1.0	32
80	Impairment of circulating endothelial progenitors in Down syndrome. <i>BMC Medical Genomics</i> , 2010, 3, 40.	1.5	36
81	Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study. <i>Haematologica</i> , 2010, 95, 644-650.	3.5	273
82	Contrast-enhanced Harmonic Compound US of the Spleen to Increase Staging Accuracy in Patients with Hodgkin Lymphoma: A Prospective Study. <i>Radiology</i> , 2009, 251, 574-582.	7.3	37
83	Cytologic, flow cytometry, and molecular assessment of lymphoid infiltrate in fineâ€needle cytology samples of Hashimoto thyroiditis. <i>Cancer Cytopathology</i> , 2009, 117, 174-184.	2.4	39
84	Clonal Bâ€cell population in a reactive lymph node in acquired immunodeficiency syndrome. <i>Diagnostic Cytopathology</i> , 2009, 37, 910-914.	1.0	30
85	Fineâ€needle aspiration cytology in the followâ€up of Hodgkin lymphoma. <i>Diagnostic Cytopathology</i> , 2008, 36, 467-472.	1.0	5
86	Imatinib mesylate therapy in chronic myeloid leukemia patients in stable complete cytogenic response after interferon-alpha results in a very high complete molecular response rate. <i>Leukemia Research</i> , 2008, 32, 255-261.	0.8	13
87	Excellent prognosis and prevalence of HCV infection of primary hepatic and splenic nonâ€Hodgkinâ€™s lymphoma. <i>European Journal of Haematology</i> , 2008, 81, 51-57.	2.2	39
88	Invasive fungal infections in patients with acute myeloid leukemia and in those submitted to allogeneic hemopoietic stem cell transplant: who is at highest risk?. <i>European Journal of Haematology</i> , 2008, 81, 242-243.	2.2	38
89	Improved Management of Neutropenic Enterocolitis Using Early Ultrasound Scan and Vigorous Medical Treatment. <i>Clinical Infectious Diseases</i> , 2007, 45, 403-404.	5.8	12
90	Invasive Aspergillosis in Patients with Acute Leukemia: Update on Morbidity and Mortalityâ€SEIFEM-C Report. <i>Clinical Infectious Diseases</i> , 2007, 44, 1524-1525.	5.8	102

#	ARTICLE	IF	CITATIONS
91	Randomized comparison of consolidation radiation <i>versus</i> observation in bulky Hodgkin's lymphoma with post-chemotherapy negative positron emission tomography scans. Leukemia and Lymphoma, 2007, 48, 1721-1727.	1.3	129
92	Clinical Relevance of Intrahepatic Hepatitis B Virus DNA in HBsAg-negative HBcAb-positive Patients Undergoing Hematopoietic Stem Cell Transplantation for Hematological Malignancies. Transplantation, 2006, 82, 141.	1.0	19
93	Estimation of bulky lymph nodes by power Doppler ultrasound scanning in patients with Hodgkin's lymphoma: a prospective study. Haematologica, 2006, 91, 960-3.	3.5	11
94	The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica, 2006, 91, 1068-75.	3.5	650
95	Randomized Comparison of Power Doppler Ultrasound-Directed Excisional Biopsy With Standard Excisional Biopsy for the Characterization of Lymphadenopathies in Patients With Suspected Lymphoma. Journal of Clinical Oncology, 2004, 22, 3733-3740.	1.6	30
96	Toxoplasma gondii infection in patients with hematological malignancies. Annals of Hematology, 2004, 83, 592-595.	1.8	25
97	Fine-needle cytology and flow cytometry immunophenotyping and subclassification of non-hodgkin lymphoma. Cancer, 2003, 102, 55-65.	4.1	117
98	Intestinal toxicity during induction chemotherapy with cytarabine-based regimens in adult acute myeloid leukemia. The Hematology Journal, 2003, 4, 346-350.	1.4	26
99	Hepatitis B virus reactivation after fludarabine-based regimens for indolent non-Hodgkin's lymphomas: high prevalence of acquired viral genomic mutations. Haematologica, 2003, 88, 1296-303.	3.5	41
100	Measurement of spleen volume by ultrasound scanning in patients with thrombocytosis: a prospective study. Blood, 2002, 99, 4228-4230.	1.4	42
101	Efficacy of lamivudine to prevent hepatitis reactivation in hepatitis B virus-infected patients treated for non-Hodgkin lymphoma. Blood, 2002, 99, 724-725.	1.4	68
102	Fine-needle aspiration biopsy and flow cytometry immunophenotyping of lymphoid and myeloproliferative disorders of the spleen. Cancer, 2002, 99, 118-127.	4.1	29
103	Expression of NK-associated antigens in extramedullary lymph nodal blast crisis of chronic myeloid leukemia on fine-needle cytology. Diagnostic Cytopathology, 2002, 27, 158-160.	1.0	7
104	<i>Pneumocystis carinii</i> pneumonia in patients with malignant haematological diseases: 10 years' experience of infection in GIMEMA centres. British Journal of Haematology, 2002, 117, 379-386.	2.5	123
105	High prevalence of hepatitis C virus infection in patients with B-cell lymphoproliferative disorders in Italy. , 1997, 55, 77-82.		82